- Conditions
- Attention Deficit Hyperactivity Disorder (ADHD)
- Interventions
- SPN-810 (18 mg), SPN-810 (36 mg), Placebo
- Drug
- Lead sponsor
- Supernus Pharmaceuticals, Inc.
- Industry
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 333 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 28
- States / cities
- Rogers, Arkansas • Culver City, California • Glendale, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2024 · Synced May 22, 2026, 3:45 AM EDT